PharmacoEconomics

1997 - 2022

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Track citations for all items by RSS feed
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 40, issue 5, 2022

Exploring the Issues of Valuing Child and Adolescent Health States Using a Mixed Sample of Adolescents and Adults pp. 479-488

Donna Rowen, Clara Mukuria, Philip A. Powell and Allan Wailoo

Assessments of the Value of New Interventions Should Include Health Equity Impact pp. 489-495

Jeroen P. Jansen, Thomas A. Trikalinos and Kathryn A. Phillips

Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches pp. 497-507

Elamin H. Elbasha

Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 509-518

Sabine E. Grimm, Willem Witlox, Robert Wolff, Annette Chalker, Mickael Hiligsmann, Ben Wijnen, Charlotte Ahmadu, Steve Ryder, Nigel Armstrong, Steven Duffy, Isabel Syndikus, Jos Kleijnen and Manuela A. Joore

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review pp. 519-558

Min Huang, Amin Haiderali, Grace E. Fox, Andrew Frederickson, Javier Cortes, Peter A. Fasching and Joyce O’Shaughnessy

The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England pp. 559-574

K. Ray Chaudhuri, A. Simon Pickard, Ali Alobaidi, Yash J. Jalundhwala, Prasanna L. Kandukuri, Yanjun Bao, Julia Sus, Glynn Jones, Christian Ridley, Julia Oddsdottir, Seyavash Najle-Rahim, Matthew Madin-Warburton, Weiwei Xu and Anette Schrag

Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 575-575

Sabine E. Grimm, Willem Witlox, Robert Wolff, Annette Chalker, Mickael Hiligsmann, Ben Wijnen, Charlotte Ahmadu, Steve Ryder, Nigel Armstrong, Steven Duffy, Isabel Syndikus, Jos Kleijnen and Manuela A. Joore

Volume 40, issue 4, 2022

Calibrating Natural History of Cancer Models in the Presence of Data Incompatibility: Problems and Solutions pp. 359-366

Olena Mandrik, Chloe Thomas, Sophie Whyte and James Chilcott

Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice pp. 367-378

Manuel Gomes, Elizabeth Murray and James Raftery

Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures pp. 379-431

Joseph Kwon, Louise Freijser, Elisabeth Huynh, Martin Howell, Gang Chen, Kamran Khan, Shahd Daher, Nia Roberts, Conrad Harrison, Sarah Smith, Nancy Devlin, Kirsten Howard, Emily Lancsar, Cate Bailey, Jonathan Craig, Kim Dalziel, Alison Hayes, Brendan Mulhern, Germaine Wong, Julie Ratcliffe and Stavros Petrou

The EQ-5D-5L Valuation Study in Egypt pp. 433-447

Sahar Al Shabasy, Maggie Abbassi, Aureliano Finch, Bram Roudijk, Darrin Baines and Samar Farid

Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia pp. 449-460

Kaitlyn Hastings, Clara Marquina, Jedidiah Morton, Dina Abushanab, Danielle Berkovic, Stella Talic, Ella Zomer, Danny Liew and Zanfina Ademi

Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine pp. 461-476

Zoë Pieters, Benson Ogunjimi, Philippe Beutels and Joke Bilcke

Correction to: Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures pp. 477-478

Joseph Kwon, Louise Freijser, Elisabeth Huynh, Martin Howell, Gang Chen, Kamran Khan, Shahd Daher, Nia Roberts, Conrad Harrison, Sarah Smith, Nancy Devlin, Kirsten Howard, Emily Lancsar, Cate Bailey, Jonathan Craig, Kim Dalziel, Alison Hayes, Brendan Mulhern, Germaine Wong, Julie Ratcliffe and Stavros Petrou

Volume 40, issue 3, 2022

Four Aspects Affecting Health Economic Decision Models and Their Validation pp. 241-248

Talitha Feenstra, Isaac Corro-Ramos, Dominique Hamerlijnck, George Voorn and Salah Ghabri

Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time pp. 249-256

Gemma E. Shields, Becky Pennington, Ash Bullement, Stuart Wright and Jamie Elvidge

Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models pp. 257-268

Min Huang, Scott Ramsey, Weiguang Xue, Jipan Xie, James Pellissier and Andrew Briggs

Deprescribing Interventions among Community-Dwelling Older Adults: A Systematic Review of Economic Evaluations pp. 269-295

Sónia Romano, Débora Figueira, Inês Teixeira and Julian Perelman

A Comparison of PROPr and EQ-5D-5L Value Sets pp. 297-307

Tianxin Pan, Brendan Mulhern, Rosalie Viney, Richard Norman, Janel Hanmer and Nancy Devlin

Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol pp. 309-321

Fan Yang, Kenneth R. Katumba, Bram Roudijk, Zhihao Yang, Paul Revill, Susan Griffin, Perez N. Ochanda, Mohammed Lamorde, Giulia Greco, Janet Seeley and Mark Sculpher

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom pp. 323-339

Timothy Spelman, William L. Herring, Yuanhui Zhang, Michael Tempest, Isobel Pearson, Ulrich Freudensprung, Carlos Acosta, Thibaut Dort, Robert Hyde, Eva Havrdova, Dana Horakova, Maria Trojano, Giovanna Luca, Alessandra Lugaresi, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Raed Alroughani, Eugenio Pucci, Franco Granella, Jeannette Lechner-Scott, Patrizia Sola, Diana Ferraro, Francois Grand’Maison, Murat Terzi, Csilla Rozsa, Cavit Boz, Raymond Hupperts, Vincent Pesch, Celia Oreja-Guevara, Anneke Walt, Vilija G. Jokubaitis, Tomas Kalincik and Helmut Butzkueven

Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment pp. 341-354

Gabin F. Morillon and Thomas G. Poder

Correction to: Contextual Considerations and Recommendations for Estimating the Value of Alzheimer’s Disease Therapies pp. 355-355

T. Joseph Mattingly, R. Brett McQueen and Pei-Jung Lin

Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment pp. 357-357

Gabin F. Morillon and Thomas G. Poder

Volume 40, issue 2, 2022

Future Offspring Costs in Economic Evaluation pp. 141-147

Evelyn Verbeke and Jeroen Luyten

Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency pp. 149-156

Gemma E. Shields, Mark Wilberforce, Paul Clarkson, Tracey Farragher, Arpana Verma and Linda M. Davies

How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents pp. 157-182

Cate Bailey, Kim Dalziel, Paula Cronin, Nancy Devlin and Rosalie Viney

Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review pp. 183-201

Thitima Kongnakorn, Grammati Sarri, Andreas Freitag, Kinga Marczell, Paulina Kazmierska, Elizabeth Masters, Vivek Pawar and Xinke Zhang

The Utility of a Rapid Review Evaluation Process to a National HTA Agency pp. 203-214

Áine Varley, Lesley Tilson, Emer Fogarty, Laura McCullagh and Michael Barry

The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions pp. 215-223

Yan Meng, Philip M. Clarke and Ilias Goranitis

Is an Orphan Drug’s Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness? pp. 225-232

James D. Chambers, Nikoletta M. Margaretos, Daniel E. Enright, Rosa Wang and Xin Ye

The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS pp. 233-239

Megan Perry-Duxbury, James Lomas, Miqdad Asaria and Pieter Baal

Volume 40, issue 1, 2022

Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain pp. 3-5

Chris Skedgel

CHEERS to 30 Years of PharmacoEconomics pp. 5-6

Richard Milne and Christopher Carswell

In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era pp. 7-11

Werner Brouwer, Samare Huls, Ayesha Sajjad, Tim Kanters, Leona Hakkaart- van Roijen and Job Exel

Importance of Patient Involvement in the Value Assessment Process: On the Way Towards Personalised Treatments pp. 7-10

Nicole Gusset

Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management pp. 11-38

Noman Paracha, Pollyanna Hudson, Stephen Mitchell and C. Simone Sutherland

The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe pp. 13-29

Natalie Bohm, Sarah Bermingham, Frank Grimsey Jones, Daniela C. Gonçalves-Bradley, Alex Diamantopoulos, Jessica R. Burton and Hamish Laing

Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates pp. 31-43

Laura C. Edney, James Lomas, Jonathan Karnon, Laura Vallejo-Torres, Niek Stadhouders, Jonathan Siverskog, Mike Paulden, Ijeoma P. Edoka and Jessica Ochalek

Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers pp. 39-67

C. Simone Sutherland, Pollyanna Hudson, Stephen Mitchell and Noman Paracha

Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review pp. 45-64

Thomas Ward, Ruben E. Mujica-Mota, Anne E. Spencer and Antonieta Medina-Lara

A General Public Study on Preferences and Welfare Impacts of Antimicrobial Resistance in the United Kingdom pp. 65-76

Maria Veronica Dorgali, Alberto Longo, Caroline Vass, Gemma Shields, Roger Harrison, Riccardo Scarpa and Marco Boeri

Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA) pp. 69-89

Noman Paracha, Pollyanna Hudson, Stephen Mitchell and C. Simone Sutherland

Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic pp. 77-90

Samare P. I. Huls, Ayesha Sajjad, Tim A. Kanters, Leona Hakkaart- van Roijen, Werner B. F. Brouwer and Job Exel

The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis pp. 91-108

Laurenske A. Visser, Marc Folcher, Claudia Delgado Simao, Biotza Gutierrez Arechederra, Encarna Escudero, Carin A. Uyl- de Groot and William Ken Redekop

Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom pp. 91-102

Siu Hing Lo, Ksenija Gorni, C. Simone Sutherland, Yasmina Martí, Andrew Lloyd and Noman Paracha

Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries pp. 103-115

Siu Hing Lo, Claire Lawrence, Yasmina Martí, Andreia Café and Andrew J. Lloyd

Biased Survival Predictions When Appraising Health Technologies in Heterogeneous Populations pp. 109-120

Daniel Gallacher, Peter Kimani and Nigel Stallard

Correction to: Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain pp. 117-117

Chris Skedgel

Correction to: Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA) pp. 119-119

Noman Paracha, Pollyanna Hudson, Stephen Mitchell and C. Simone Sutherland

An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia pp. 121-131

Marjanne A. Piena, Natalie Houwing, Carla W. Kraan, Xiaofeng Wang, Heidi Waters, Ruth A. Duffy, Suresh Mallikaarjun and Craig Bennison

Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery pp. 133-135

Kevin M. Trentino, Hamish Mace and Axel Hofmann

Authors’ Response to “Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery” pp. 137-138

Bert Avau, Hans Van Remoortel, Emmy De Buck, Veerle Compernolle and Philippe Vandekerckhove

Correction to: A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population pp. 139-139

Emily McDool, Clara Mukuria and John Brazier